Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

Go back to Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
(NASDAQ: ZYME) Delayed: 23.26 --0 (-0%)
Previous Close $23.26    52 Week High
Open $23.26    52 Week Low
Day High $23.26    P/E N/A 
Day Low $23.26    EPS
Volume 182